BridgeMD
Transfer of metformin into human breast milk and the plasma of breastfeeding children - A low intervention trial with biobanking of breast milk and plasma in Västra Götalandsregionen and Region Örebro
EU CTIS ID: 2022-501693-19-00
What this study is testing
The primary trial objective is to determine the concentration of metformin in plasma of breast fed infants of lactating women treated for Type 2 Diabetes.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Breastfeeding women treated with metformin for suspected or diagnosed type 2 diabetes mellitus (T2DM). Only women of 18 years of age and older will be asked for participation. Breastfeeding children of women that have consented to participate in the study. The guardians of the child are asked for participation.
You likely can't join if
- Previous participation in the study. Women not able to read and communicate in Swedish, Arabic, Persian or Somali. Premature children. Women with multiple births.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 0-17 years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.